Uncategorized
Roche announces phase 3 trials for lampalizumab
Roche announced the initiation of two phase 3 clinical studies for lampalizumab, an investigational drug for the treatment of geographic atrophy, at the Euretina Congress in London.The phase 3 studies are aimed to determine lampalizumab’s safety and efficacy, as well as its potential to slow the progression of geographic atrophy (GA). Researchers will also investigate whether patients with the complement factor I biomarker will benefit from the drug, according to a company press release.